TY - JOUR
TI - Interleukin-7 and interleukin-15 for cancer
AU - Zarogoulidis, P.
AU - Lampaki, S.
AU - Yarmus, L.
AU - Kioumis, I.
AU - Pitsiou, G.
AU - Katsikogiannis, N.
AU - Hohenforst-Schmidt, W.
AU - Li, Q.
AU - Huang, H.
AU - Sakkas, A.
AU - Organtzis, J.
AU - Sakkas, L.
AU - Mpoukovinas, I.
AU - Tsakiridis, K.
AU - Lazaridis, G.
AU - Syrigos, K.
AU - Zarogoulidis, K.
JO - EUROPEAN JOURNAL OF CANCER
PY - 2014
VL - 5
TODO - 9
SP - 765-773
PB - Ivyspring International Publisher
SN - null
TODO - 10.7150/jca.10471
TODO - interleukin 15;  interleukin 7, cancer immunization;  disease association;  human;  malignant neoplastic disease;  nonhuman;  randomized controlled trial (topic);  Review;  systematic review;  tumor microenvironment
TODO - Interleukin 7 and 15 are considered powerful pro-inflammatory cytokines, they have the ability to destabilize chromosomes and induce tumorigenesis. Additionally, they can control malignancy proliferation by influencing the tumor microenvironment and immune system. Immunotherapy has been proposed as a treatment modality for malignancy for over a decade; the exact mechanisms of action and pathways are still under investigation. Interleukin 7 and 15 have been extensively investigated in hematological malignancies since their mode of action influences the stimulation of the immune system in a more direct way than other malignancies such as lung, melanoma, and breast, renal and colorectal cancer. © Ivyspring International Publisher.
ER -